Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Neoplasms 1 Glioblastoma 1 Coronary Artery Disease 1 Breast Neoplasms 1

Interventions

Docetaxel 277 Prednisone 237 enzalutamide 177 Leuprolide 172 Radiotherapy 164 Abiraterone Acetate 154 Magnetic Resonance Spectroscopy 147 bicalutamide 137 Goserelin 134 Androgen Antagonists 111 Radiosurgery 101 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100 apalutamide 79 abiraterone 77 gallium 68 PSMA-11 74 Specimen Handling 67 darolutamide 58 Gonadotropin-Releasing Hormone 58 Radiation 56 Triptorelin Pamoate 53 cabazitaxel 50 Zoledronic Acid 49 pembrolizumab 48 Radiotherapy, Intensity-Modulated 47 Flutamide 47 Brachytherapy 47 luprolide acetate gel depot 46 Standard of Care 45 Carboplatin 44 Estramustine 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostatic Neoplasms × Molecular Imaging × Clear all

NCT02813226 2021-12-21

MISTER

Ontario Clinical Oncology Group (OCOG)

Phase NA Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡